<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073317</url>
  </required_header>
  <id_info>
    <org_study_id>PRES-023-PPE-15</org_study_id>
    <nct_id>NCT03073317</nct_id>
  </id_info>
  <brief_title>PREPARE, Prematurity Reduction by Pre-eclampsia Care</brief_title>
  <acronym>PREPARE</acronym>
  <official_title>PREPARE, Prematurity Reduction by Pre-eclampsia Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Fernandes Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CoLab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMSDC/RJ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HGA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Fernandes Figueira</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators will test a novel system of integrated care, to promote the use of the WORLD
      HEALTH ORGANIZATION Guidelines for the management of pre-eclampsia and initiate the use of a
      structured risk assessment strategy to reduce the incidence of preterm delivery from
      pre-eclampsia by providing obstetricians with the confidence to safely defer delivery of
      women with pre-eclampsia, identified to be of low risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal (PREPARE), led by Brazilian investigators in collaboration with the Global
      Pregnancy Collaboration (CoLab) is centred on 7 hospital centres and their 23 satellite
      community health centres (UBSs). There are two clinical initiatives: First, a programme of
      systematic knowledge transfer (KT) to encourage adoption of the WHO Guidelines to prevent
      pre-eclampsia as part of routine antenatal care (Objective 1); second an intervention to
      reduce unnecessary preterm deliveries for the management of pre-eclampsia. CoLab
      investigators have developed methods to identify those women with preterm pre-eclampsia whose
      pregnancies can be safely prolonged.4-6 In Objective 2.1, these methods will be applied to
      women presenting with definite or suspected pre-eclampsia at &lt; 37 weeks' gestation.
      Investigators will determine the likelihood of an imminent adverse outcome in these women
      using Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio (sFlT-1/PlGF)
      measurement and fullPIERS clinical assessment. Prior studies with these approaches indicate
      more than 98% negative predictive value for adverse outcomes for both.4-6 Investigators will
      delay delivery in those whose risk is low, caring for patients in accordance with
      evidence-based WHO guidelines.Unlike medications, management cannot be tested in a blinded
      way. Management needs integrated skills and commitment from caregivers. Hence, a standard
      randomized controlled trial is inappropriate. Instead investigators propose a Stepped Wedge
      Design to study outcomes in the 7 geographically diverse study centres, throughout Brazil. At
      least 6 women with preterm pre-eclampsia will deliver at each centre every month. The primary
      outcome will be a lower rate of PRETERM BIRTH due to pre-eclampsia as a proportion of total
      deliveries in the centre(s) after implementation of the plan compared to prior to its
      introduction. The study will have 80% power to demonstrate a 25% reduction (2.0 - 1.5%).
      Investigators will assess maternal and foetal adverse events as secondary outcomes. Objective
      2.2 will institute an intense program of knowledge transfer to implement the new management
      techniques. In Objectives 2.3 and 2.4 will determine patient and provider satisfaction and
      the economic impact of the care plan. In Objective 3 will establish a biobank and database to
      begin to assess demographic factors and biological analytes that may help identify unique
      predictive and diagnostic/pathophysiological features for pre-eclampsia in the Brazilian
      population (that may extend to other low and middle income countries (LMIC)). For two years
      at routine visits (≤16 weeks, 28-32 weeks) at each UBS, relevant data and plasma, serum,
      urine and DNA samples will be stored to the appropriate standards in the biorepository (at
      least 7000 cases). Investigators estimate that will acquire samples at delivery in at least
      5000 of these women. For four years, biological samples from women with pre-eclampsia or
      other adverse outcomes and 2 matched controls will be collected at admission for labour (an
      additional 3,000 subjects). Objective 4 will initiate pilot studies to identify novel
      biomarkers, and compare these and other known pathophysiological factors with those from LMIC
      (Africa, India) and HIC using samples from CoLab. Additional funding will be sought for
      expansion and validation (e.g. Merck for Mothers). Investigators will also seek funding to
      address risk stratification in apparently low risk women, based on the samples collected at
      28-32 weeks. Objective 5 will promote intellectual interactions and collaboration between the
      seven centres and CoLab. Ability to understand and cure complex adverse pregnancy outcomes
      leading to acute and long-range disability in children requires intensive collaboration
      across usual &quot;silos&quot; including hospitals and nations. The coordinators anticipate the
      interaction of investigators and care providers in the seven centres will foster intellectual
      collaboration and improved standardized care. Brazilian investigators will become members of
      CoLab, increasing its unique vision, expertise and resources (current data and biological
      materials from 28 centres). worldwide).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">December 20, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of prematurity</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>Proportion of women delivered in the centres with preterm pre-eclampsia (deliveries with preterm pre-eclampsia/ total deliveries), where preterm is &lt;37 weeks' gestation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prematurity due to pre-eclampsia</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>the proportion of women delivered with preterm pre-eclampsia/ total deliveries for pre-eclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prolongation of pregnancy</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women admitted with pre-eclampsia &lt; 37 weeks delivered after 37 weeks</time_frame>
    <description>proportion of women delivered &lt;34 weeks' gestation with pre-eclampsia/ total deliveries &lt;34 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal morbidity</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study -reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study</time_frame>
    <description>frequency of severe hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 110 mm/Hg),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of maternal hospital stay</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 34 weeks due to pre-eclampsia</time_frame>
    <description>length of maternal hospital stay of women delivered &lt;34 weeks' gestation with pre-eclampsia/ total deliveries &lt;34 weeks' gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>maternal mortality</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>cases of maternal mortality due to pre-eclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal mortrality</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - babies delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>cases of neonatal mortality due to prematurity related to pre-eclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HELLP syndrome</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>number of cases of HELLP syndrome in women with pre-eclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eclampsia</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>number of cases of eclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>reseachers will be assessing and reporting outcome through month 1 to moth 34 of the study - women delivered before 37 weeks due to pre-eclampsia</time_frame>
    <description>number of cases of stroke in women with pre-eclampsia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Pre-Eclampsia</condition>
  <condition>Premature Birth</condition>
  <arm_group>
    <arm_group_label>INTERVENTION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual clinic control</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)</intervention_name>
    <description>Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.</description>
    <arm_group_label>INTERVENTION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnancy before 16 weeks

          -  delivery at designed maternity center

        Exclusion Criteria:

          -  not viable fetus
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcos A Dias, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Fernandes Figueira</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcos A. Dias, PhD</last_name>
    <phone>552125541740</phone>
    <phone_ext>1740</phone_ext>
    <email>marcosad@centroin.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leandro G. de Oliveira, PhD</last_name>
    <phone>5514991891221</phone>
    <email>leandrogo@fmb.unesp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Gde Do Sul</state>
        <zip>90.035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAMANTHA SCHNEIDER, DOCTOR</last_name>
      <phone>55519918980140</phone>
      <email>samantasch88@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>TIAGO P DULLIUS, DOCTOR</last_name>
      <phone>555132374537</phone>
      <email>tdullius@hcpa.edu.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maternidade Unesp Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618-681</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LIVIA M CARDOZO, MD</last_name>
      <phone>551438801388</phone>
      <email>livia_cardozo@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>DUELENE L NOGUEIRA, NURSE</last_name>
      <phone>551438158327</phone>
      <email>udinogueira@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Caism - Unicamp</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13084-881</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JOSE P GUIDA, MD</last_name>
      <phone>5519981943677</phone>
      <email>ZEPAULOGUIDA@GMAIL.COM</email>
    </contact>
    <contact_backup>
      <last_name>CARLA SILVEIRA, NURSE</last_name>
      <phone>551935219472</phone>
      <email>carla_silve@yahoo.com.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Guilherme Alvaro</name>
      <address>
        <city>Santos</city>
        <state>Sao Paulo</state>
        <zip>11045-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IVETE L TROTTI, NURSE</last_name>
      <phone>5513991153808</phone>
      <email>ivtrotti@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>CLAUDIA C SIQUEIRA, NURSE</last_name>
      <phone>5513981311110</phone>
      <email>clau.siqueira92@yahoo.com.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Instituto Fernandes Figueira</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20021140</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MARCOS NAKAMURA, MD</last_name>
      <phone>25541700</phone>
      <phone_ext>1810</phone_ext>
      <email>&lt;marcosnakamura@globo.com&gt;</email>
    </contact>
    <contact_backup>
      <last_name>GUILHERME JESUS, MD</last_name>
      <phone>25541700</phone>
      <phone_ext>1810</phone_ext>
      <email>&lt;guilhermedejesus@gmail.com&gt;</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maternidade Maria Amelia Buarque de Holanda</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20211-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CAMILA IUNG, DOCTOR</last_name>
      <phone>552134493243</phone>
      <email>camila.costa@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>MICHELLE MENDES, NURSE</last_name>
      <phone>5521984259203</phone>
      <email>enfmichelle2008@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maternidade Leila Diniz</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>22775-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LUCIENNE FRAYHA, DOCTOR</last_name>
      <phone>552124915326</phone>
      <email>frayha@globo.com</email>
    </contact>
    <contact_backup>
      <last_name>lUCIANA M ARAUJO, NURSE</last_name>
      <phone>552124245552</phone>
      <email>lumaraujorj@yahoo.com.br</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Maternidade Leonor Mendes de Barros</name>
      <address>
        <city>Sao Paulo</city>
        <zip>03015-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ROSANGELA A DIAS, NURSE</last_name>
      <phone>551122924188</phone>
      <email>roaledias@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>ANA MADALENA, NURSE</last_name>
      <phone>551127473910</phone>
      <email>ana.lhamas@ig.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ananth CV, Vintzileos AM. Medically indicated preterm birth: recognizing the importance of the problem. Clin Perinatol. 2008 Mar;35(1):53-67, viii. doi: 10.1016/j.clp.2007.11.001. Review.</citation>
    <PMID>18280875</PMID>
  </reference>
  <results_reference>
    <citation>Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005 Jun 10;308(5728):1592-4. Review.</citation>
    <PMID>15947178</PMID>
  </results_reference>
  <results_reference>
    <citation>WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization; 2011.</citation>
    <PMID>23741776</PMID>
  </results_reference>
  <results_reference>
    <citation>Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016 Jan 7;374(1):13-22. doi: 10.1056/NEJMoa1414838.</citation>
    <PMID>26735990</PMID>
  </results_reference>
  <results_reference>
    <citation>von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F, Côté AM, Douglas MJ, Gruslin A, Hutcheon JA, Joseph KS, Kyle PM, Lee T, Loughna P, Menzies JM, Merialdi M, Millman AL, Moore MP, Moutquin JM, Ouellet AB, Smith GN, Walker JJ, Walley KR, Walters BN, Widmer M, Lee SK, Russell JA, Magee LA; PIERS Study Group. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011 Jan 15;377(9761):219-27. doi: 10.1016/S0140-6736(10)61351-7. Epub 2010 Dec 23.</citation>
    <PMID>21185591</PMID>
  </results_reference>
  <results_reference>
    <citation>Dantas EM, Pereira FV, Queiroz JW, Dantas DL, Monteiro GR, Duggal P, Azevedo Mde F, Jeronimo SM, Araújo AC. Preeclampsia is associated with increased maternal body weight in a northeastern Brazilian population. BMC Pregnancy Childbirth. 2013 Aug 8;13:159. doi: 10.1186/1471-2393-13-159.</citation>
    <PMID>23927768</PMID>
  </results_reference>
  <results_reference>
    <citation>Kajantie E, Eriksson JG, Osmond C, Thornburg K, Barker DJ. Pre-eclampsia is associated with increased risk of stroke in the adult offspring: the Helsinki birth cohort study. Stroke. 2009 Apr;40(4):1176-80. doi: 10.1161/STROKEAHA.108.538025. Epub 2009 Mar 5.</citation>
    <PMID>19265049</PMID>
  </results_reference>
  <results_reference>
    <citation>Passini R Jr, Tedesco RP, Marba ST, Cecatti JG, Guinsburg R, Martinez FE, Nomura ML; Brazilian Network of Studies on Reproductive and Perinatal Health. Brazilian multicenter study on prevalence of preterm birth and associated factors. BMC Pregnancy Childbirth. 2010 May 19;10:22. doi: 10.1186/1471-2393-10-22.</citation>
    <PMID>20482822</PMID>
  </results_reference>
  <results_reference>
    <citation>Camargo EB, Moraes LF, Souza CM, Akutsu R, Barreto JM, da Silva EM, Betrán AP, Torloni MR. Survey of calcium supplementation to prevent preeclampsia: the gap between evidence and practice in Brazil. BMC Pregnancy Childbirth. 2013 Nov 11;13:206. doi: 10.1186/1471-2393-13-206.</citation>
    <PMID>24215470</PMID>
  </results_reference>
  <results_reference>
    <citation>Chappell LC, Milne F, Shennan A. Is early induction or expectant management more beneficial in women with late preterm pre-eclampsia? BMJ. 2015 Apr 10;350:h191. doi: 10.1136/bmj.h191. Review.</citation>
    <PMID>25861796</PMID>
  </results_reference>
  <results_reference>
    <citation>Vigil-De Gracia P, Reyes Tejada O, Calle Miñaca A, Tellez G, Chon VY, Herrarte E, Villar A, Ludmir J. Expectant management of severe preeclampsia remote from term: the MEXPRE Latin Study, a randomized, multicenter clinical trial. Am J Obstet Gynecol. 2013 Nov;209(5):425.e1-8. doi: 10.1016/j.ajog.2013.08.016. Epub 2013 Aug 14.</citation>
    <PMID>23954534</PMID>
  </results_reference>
  <results_reference>
    <citation>von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143-8. Review.</citation>
    <PMID>12908998</PMID>
  </results_reference>
  <results_reference>
    <citation>Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol. 2006 Nov 8;6:54. Review.</citation>
    <PMID>17092344</PMID>
  </results_reference>
  <results_reference>
    <citation>Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster randomized trials. Contemp Clin Trials. 2007 Feb;28(2):182-91. Epub 2006 Jul 7. Review.</citation>
    <PMID>16829207</PMID>
  </results_reference>
  <results_reference>
    <citation>Harvey G, Loftus-Hills A, Rycroft-Malone J, Titchen A, Kitson A, McCormack B, Seers K. Getting evidence into practice: the role and function of facilitation. J Adv Nurs. 2002 Mar;37(6):577-88. Review.</citation>
    <PMID>11879422</PMID>
  </results_reference>
  <results_reference>
    <citation>von Dadelszen P, Sawchuck D, McMaster R, Douglas MJ, Lee SK, Saunders S, Liston RM, Magee LA; Translating Evidence-Based Surveillance and Treatment Strategies (TESS) Group. The active implementation of pregnancy hypertension guidelines in British Columbia. Obstet Gynecol. 2010 Sep;116(3):659-66. doi: 10.1097/AOG.0b013e3181eb669d.</citation>
    <PMID>20733449</PMID>
  </results_reference>
  <results_reference>
    <citation>Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009 Mar;30 Suppl A:S32-7. doi: 10.1016/j.placenta.2008.11.009. Epub 2008 Dec 13.</citation>
    <PMID>19070896</PMID>
  </results_reference>
  <results_reference>
    <citation>Myers JE, Kenny LC, McCowan LM, Chan EH, Dekker GA, Poston L, Simpson NA, North RA; SCOPE consortium. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG. 2013 Sep;120(10):1215-23. doi: 10.1111/1471-0528.12195. Epub 2013 Mar 21.</citation>
    <PMID>23906160</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Fernandes Figueira</investigator_affiliation>
    <investigator_full_name>Marcos Augusto Bastos Dias</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Preterm Infants</keyword>
  <keyword>Premature Birth</keyword>
  <keyword>Placenta growth factor</keyword>
  <keyword>Prenatal Care</keyword>
  <keyword>PERINATAL MORTALITY</keyword>
  <keyword>Pre-Eclampsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

